Exenatide LAR Phase III Non-Inferiority Data Anticipated In Q4, Amylin Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is also on track to finalize commercial manufacturing for the once weekly form of Byetta in the second half of 2008.
You may also be interested in...
Amylin/Lilly’s Once-Weekly Exenatide Wins Head-To-Head Over Byetta
Firms expect to file NDA by end of first half 2009.
Amylin/Lilly’s Once-Weekly Exenatide Wins Head-To-Head Over Byetta
Firms expect to file NDA by end of first half 2009.
Amylin Will Add Pancreatitis Cautions To Byetta Label
FDA issues Medwatch alert warning health care professionals of 30 cases of acute pancreatitis in patients taking the type 2 diabetes drug